Home BMY
  Price0.31%   +0.25
(After Hours: 80.80 -0.33 -0.41%)

Bristol-Myers Squibb Company (BMY) Latest News

Dec-02-22 11:31AM Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research
09:00AM Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to KnowZacks Investment Research
Dec-01-22 11:31AM Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research
10:12AM bluebird (BLUE) to Boost Cash With Priority Review Voucher SaleZacks Investment Research
Dec-01-22 09:05AM The Top Healthcare Stocks to Buy With $100The Motley Fool
Nov-30-22 10:06AM Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?The Motley Fool
08:20AM 2 Massive Companies That Have Doubled Their Sales in 5 YearsThe Motley Fool
Nov-29-22 05:45AM Alexandria Real Estate Stock: Bull vs. BearThe Motley Fool
Nov-28-22 01:01AM Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day SessionBenzinga
10:27AM US Stocks Start Week On Lower Note, Dow Drops Over 100 PointsBenzinga
Nov-26-22 06:05AM 3 Dividend Stocks to Hold ForeverThe Motley Fool
Nov-24-22 11:31AM Why Is Bristol Myers (BMY) Up 6.3% Since Last Earnings Report?Zacks Investment Research
10:22AM Mirati's (MRTX) Stock Rallies 11% on Buyout SpeculationsZacks Investment Research
Nov-24-22 10:15AM Is Now the Time for Income Investors to Buy This Big Pharma Stock?The Motley Fool
Nov-23-22 12:16PM Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets GoalZacks Investment Research
Nov-22-22 10:07AM Prothena (PRTA) Earns Milestone Payment From Novo NordiskZacks Investment Research
09:45AM 2 Reasons to Buy AbbVie Stock and 1 Reason to SellThe Motley Fool
Nov-21-22 12:24PM Bristol Myers (BMY) Gains 24.2% YTD: What's in Store for 2023?Zacks Investment Research
12:11PM Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma DrugZacks Investment Research
Nov-19-22 09:00AM 'The Big Short' Michael Burry Buys Real Assets Hand Over FistSeeking Alpha
Nov-18-22 02:42AM Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol MyersBenzinga
01:00AM Where Bristol-Myers Squibb Stands With AnalystsBenzinga
Nov-18-22 11:58AM Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022Benzinga
09:37AM 2 Stocks to Buy Whether or Not a Recession Is ComingThe Motley Fool
Nov-18-22 07:02AM 8 Analysts Have This to Say About Bristol-Myers SquibbBenzinga
Nov-15-22 08:56AM JPMorgan Chase, Bristol-Myers Squibb And 3 Other Stocks Insiders Are SellingBenzinga
Nov-11-22 10:23AM Is This Blue-Chip Dividend Stock a Buy?The Motley Fool
Nov-10-22 10:40AM Bristol-Myers Squibb To Surge Over 10%? Plus Morgan Stanley Predicts $263 For L3Harris TechnologiesBenzinga
08:15AM 2 Ultra-Safe Passive Income Stocks to Buy Right NowThe Motley Fool
Nov-09-22 09:53AM Here's Why This Growth Stock Is Already My 2022 WinnerThe Motley Fool
09:47AM Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales BeatZacks Investment Research
Nov-08-22 07:45AM Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend StocksThe Motley Fool
Nov-04-22 07:45AM A $10,000 Investment at the Start of the Great Recession Would Be Worth This Much TodayThe Motley Fool
Nov-02-22 11:23AM Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids GrowthZacks Investment Research
Nov-01-22 11:39AM Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales ViewZacks Investment Research
Oct-27-22 02:37AM Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In StockBenzinga
01:30AM Wingstop To Rally Around 13%? Plus This Analyst Cuts PT On Cano Health By 50%Benzinga
Oct-27-22 10:23AM If You Invested $10,000 in Bristol Myers Squibb 5 Years Ago, This Is How Much You Would Have TodayThe Motley Fool
10:08AM Where Bristol-Myers Squibb Stands With AnalystsBenzinga
Oct-27-22 10:00AM Analyst Ratings for Bristol-Myers SquibbBenzinga
05:52AM Is Bristol Myers Squibb Stock a Buy With Its New-Product Sales Soaring?The Motley Fool
Oct-27-22 04:20AM Strong Fundamentals Make Bristol Myers Squibb Stock A Real ValueInvesting.com
Oct-26-22 02:00AM Bristol Myers Squibb (BMY) Q3 2022 Earnings Call TranscriptThe Motley Fool
12:19PM Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/YZacks Investment Research
Oct-26-22 12:07PM Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study UpdateZacks Investment Research
09:45AM Two Warren Buffett Rules You Should Never ForgetThe Motley Fool
Oct-26-22 05:19AM Nasdaq, S&P 500 Futures Lower Following Alphabet, Microsoft EarningsBenzinga
Oct-25-22 08:55AM Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research
09:07AM 2 Pharma Stocks With Blockbuster Drugs on the HorizonThe Motley Fool
Oct-24-22 08:30AM 2 No-Brainer Healthcare Stocks to Buy Right NowThe Motley Fool
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Cap:    |  Volume (24h):